Crucell Terug naar discussie overzicht

Events

1. [verwijderd] 7 november 2007 18:48

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Maxen:
   Crucell PER.C6® cell line – best option for yields and scalability
   en.sanofi-aventis.com/Images/070917_s...
   Sanofi's grafiek op p130 (131) van presentatie:
   
   In 20.000 litervat is, na 100 dagen, de concentratie van Per.C6 cellen gelijk aan 50 * 10^5 /ml. Hoeveel cellen zitten er dan in het vat?
   
   20.000 liter is 20.000.000 ml, dus in totaal:
   50*10^5 *20*10^6 = 1000*10^11 = 1*10^14 =
   
   = 100.000.000.000.000 cellen,
   
   oftewel (europees) 100 biljoen = 0.1 biljard,
   oftewel (amerikaans) 100 trillion = 0.1 quadrillion.
   
   (ongeveer 15.000 Per.C6 cellen per wereldbewoner, of ongeveer 1.5 miljoen cellen per Crucell aandeel)
   crucell.yourbb.nl/viewtopic.php?t=28&...
   
2. aossa 7 november 2007 18:55

   auteur info

   • aossa

     Lid sinds: 23 mei 2003

     Laatste bezoek: 27 mrt 2025

   • Aanbevelingen

     Ontvangen: 4053

     Gegeven: 3339

   •    Aantal posts: 17.622

   Na de speeltijd en het afreageren van de frustraties weer naar de dagorde van dit draadje:
   
   /copy: gocrucellgo 5 nov 07, 23:00
   
   5 - 7 November 2007, Hotel Sofitel Bellecour, Lyon, France (zie draadje)
   The 3rd annual European Antibody Congress
   
   8 November 2007 PERCIVIA 1 jaar na opening.
   
   Friday, 9 November 2007 09:00 – 17:00
   38th Union World Conference on Lung Health
   Cape Town, South Africa
   www.worldlunghealth.org/Conf2007/webs...
   
   MONDAY, NOVEMBER 12, 2007 - 09:00-10:30 BIO-EUROPE
   From Target to Clinic – Reduce the Time to Your First Important Milestone
   Dr. Jelto Swaving, Manager Upstream Process Development, DSM Biologics
   Dr. Ronald Vogels, Director Protein Expression and Cell Biology, Crucell Holland BV
   www.ebdgroup.com/bioeurope/ws_panels.htm
   
   Dinsdag 13 november 2007
   Q3 2007
   
   28-11-2007
   Crucell Company visit
   
   November 30, 2007 in Bangkok, Thailand
   Joint International Tropical
   Medicine Meeting 2007
   Data from the Phase I clinical trial in India, to assess safety and
   efficacy, will be reported.
   
   Mon 03 Dec 2007 - Thu 06 Dec 2007
   Comparability Strategies for Supporting Manufacturing Scale Up of Merck’s HPV Vaccine GARDASIL®/SILGARD®
   Taking a closer look at recent PER.C6 human cell line developments
   Dr Fons UytdeHaag, Director Corporate Scientific
   Affairs, Crucell NV, The Netherlands
   www.iir-events.com/IIR-conf/LifeScien...
   
   December 04 - 06, 2007 · Sheraton San Diego Hotel and Marina · San Diego, CA
   Advancing Clinical and Preclinical Development of Therapeutic Antibodies and Antibody Conjugates
   9:15 Innovation in Human Monoclonal Antibody Production: Transient and Stable High Level Expression in PER.C6 and New Ways to Improve Yields and Lower Investments
   Abstract to come.
   Jaap Goudsmit, M.D., Chief Scientific Officer, Crucell, The Netherlands
   www.ibclifesciences.com/D4173/8074.xml
   
   Friday, January 11
   Protein Production Conference
   11:30 Highly Efficient Expression of Recombinant Proteins in PER.C6 Cells: Impact on the Design of Manufacturing Facilities.
   Marco A. Cacciuttolo, Ph.D., Chief Executive Officer, PERCIVIA LLC
   Due to the highly efficient nature of PER.C6® cells both (1) to grow in suspension cultures at extremely high cell densities and (2) to express recombinant product on a per-cell basis without the need for amplification at high specific yields, the PER.C6® Technology Platform has to address the need to manufacture, recover, and purify proteins economically and efficiently. In this presentation, a revolutionary concept for making biologics in small footprint facilities, using disposable technologies is discussed. This design takes advantage of the high specific productivity in each of the Upstream and Downstream unit operations achieved when using the PER.C6® Technology Platform.
   www.chi-peptalk.com/08_PPD_day2.asp
   
   Monday ‐ January 28, 2008
   16.30 – 17.00 ‘Ebola vaccination’
   Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.
   www.ewi.med.uu.nl/CTID/Programme_CTID...
   
   12-02-2008
   Crucell Jaarcijfers 2007 (voorbeurs)
   
   HIV Pathogenesis (X8)
   Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
   Saturday, March 29
   8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
   Dan H. Barouch, Beth Israel Deaconess Medical Center
   Novel Adenovirus Vectors
   Sunday, March 30
   8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
   Jaap Goudsmit, Crucell Holland B.V.
   Flu, TB
   www.keystonesymposia.org/Meetings/Vie...
   
   21 – 24 April, 2008
   World vaccine Congress 2008
   Gold sponsor Crucell (zie draadje)
   www.terrapinn.com/2008/wvc_DC/index.stm
   crucell.yourbb.nl/viewtopic.php?t=11&...
   
   
3. [verwijderd] 14 november 2007 16:34

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   28-11-2007
   Crucell Company visit
   
   November 30, 2007 in Bangkok, Thailand
   Joint International Tropical
   Medicine Meeting 2007
   Data from the Phase I clinical trial in India, to assess safety and
   efficacy, will be reported.
   
   Mon 03 Dec 2007 - Thu 06 Dec 2007
   Comparability Strategies for Supporting Manufacturing Scale Up of Merck’s HPV Vaccine GARDASIL®/SILGARD®
   Taking a closer look at recent PER.C6 human cell line developments
   Dr Fons UytdeHaag, Director Corporate Scientific
   Affairs, Crucell NV, The Netherlands
   www.iir-events.com/IIR-conf/LifeScien...
   
   December 04 - 06, 2007 · Sheraton San Diego Hotel and Marina · San Diego, CA
   Advancing Clinical and Preclinical Development of Therapeutic Antibodies and Antibody Conjugates
   9:15 Innovation in Human Monoclonal Antibody Production: Transient and Stable High Level Expression in PER.C6 and New Ways to Improve Yields and Lower Investments
   Abstract to come.
   Jaap Goudsmit, M.D., Chief Scientific Officer, Crucell, The Netherlands
   www.ibclifesciences.com/D4173/8074.xml
   
   Friday, January 11
   Protein Production Conference
   11:30 Highly Efficient Expression of Recombinant Proteins in PER.C6 Cells: Impact on the Design of Manufacturing Facilities.
   Marco A. Cacciuttolo, Ph.D., Chief Executive Officer, PERCIVIA LLC
   Due to the highly efficient nature of PER.C6® cells both (1) to grow in suspension cultures at extremely high cell densities and (2) to express recombinant product on a per-cell basis without the need for amplification at high specific yields, the PER.C6® Technology Platform has to address the need to manufacture, recover, and purify proteins economically and efficiently. In this presentation, a revolutionary concept for making biologics in small footprint facilities, using disposable technologies is discussed. This design takes advantage of the high specific productivity in each of the Upstream and Downstream unit operations achieved when using the PER.C6® Technology Platform.
   www.chi-peptalk.com/08_PPD_day2.asp
   
   Monday ‐ January 28, 2008
   16.30 – 17.00 ‘Ebola vaccination’
   Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.
   www.ewi.med.uu.nl/CTID/Programme_CTID...
   
   12-02-2008
   Crucell Jaarcijfers 2007 (voorbeurs)
   
   HIV Pathogenesis (X8)
   Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
   Saturday, March 29
   8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
   Dan H. Barouch, Beth Israel Deaconess Medical Center
   Novel Adenovirus Vectors
   Sunday, March 30
   8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
   Jaap Goudsmit, Crucell Holland B.V.
   Flu, TB
   www.keystonesymposia.org/Meetings/Vie...
   
   21 – 24 April, 2008
   World vaccine Congress 2008
   Gold sponsor Crucell (zie draadje)
   Congress day two
   11.35 Adenoviral vaccines against emerging and poverty-related diseases
   Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
   Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
   Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
   Dr Jaap Goudsmit, Chief Scientific Officer,
   Crucell
   Ook AdImmune, Vaxin enz
   www.terrapinn.com/2008/wvc_DC/program...
4. [verwijderd] 17 november 2007 20:32

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   28-11-2007
   Crucell Company visit
   
   November 30, 2007 in Bangkok, Thailand
   Joint International Tropical
   Medicine Meeting 2007
   Data from the Phase I clinical trial in India, to assess safety and
   efficacy, will be reported.
   
   Mon 03 Dec 2007 - Thu 06 Dec 2007
   Comparability Strategies for Supporting Manufacturing Scale Up of Merck’s HPV Vaccine GARDASIL®/SILGARD®
   Taking a closer look at recent PER.C6 human cell line developments
   Dr Fons UytdeHaag, Director Corporate Scientific
   Affairs, Crucell NV, The Netherlands
   www.iir-events.com/IIR-conf/LifeScien...
   
   December 04 - 06, 2007 · Sheraton San Diego Hotel and Marina · San Diego, CA
   Advancing Clinical and Preclinical Development of Therapeutic Antibodies and Antibody Conjugates
   9:15 Innovation in Human Monoclonal Antibody Production: Transient and Stable High Level Expression in PER.C6 and New Ways to Improve Yields and Lower Investments
   Abstract to come.
   Jaap Goudsmit, M.D., Chief Scientific Officer, Crucell, The Netherlands
   www.ibclifesciences.com/D4173/8074.xml
   
   Dec. 12
   Concerns about safety have pushed back a trial of a government-developed vaccine that contains adenovirus. The U.S. National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, will hold a meeting of researchers Dec. 12 to determine whether or how to proceed with the vaccine trial.
   www.bloomberg.com/apps/news?pid=20601...
   
   Friday, January 11
   Protein Production Conference
   11:30 Highly Efficient Expression of Recombinant Proteins in PER.C6 Cells: Impact on the Design of Manufacturing Facilities.
   Marco A. Cacciuttolo, Ph.D., Chief Executive Officer, PERCIVIA LLC
   Due to the highly efficient nature of PER.C6® cells both (1) to grow in suspension cultures at extremely high cell densities and (2) to express recombinant product on a per-cell basis without the need for amplification at high specific yields, the PER.C6® Technology Platform has to address the need to manufacture, recover, and purify proteins economically and efficiently. In this presentation, a revolutionary concept for making biologics in small footprint facilities, using disposable technologies is discussed. This design takes advantage of the high specific productivity in each of the Upstream and Downstream unit operations achieved when using the PER.C6® Technology Platform.
   www.chi-peptalk.com/08_PPD_day2.asp
   
   Monday ‐ January 28, 2008
   16.30 – 17.00 ‘Ebola vaccination’
   Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.
   www.ewi.med.uu.nl/CTID/Programme_CTID...
   
   12-02-2008
   Crucell Jaarcijfers 2007 (voorbeurs)
   
   HIV Pathogenesis (X8)
   Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
   Saturday, March 29
   8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
   Dan H. Barouch, Beth Israel Deaconess Medical Center
   Novel Adenovirus Vectors
   Sunday, March 30
   8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
   Jaap Goudsmit, Crucell Holland B.V.
   Flu, TB
   www.keystonesymposia.org/Meetings/Vie...
   
   14-17 April 2008, Oegstgeest, NL
   Development of Biopharmaceuticals as
   Innovative Drugs
   Scientific Advisory Board
   Prof. Dr. E. Hack, Crucell
   Project management and product development (Michel Briejer,Crucell)
   IP issues (Bart Klein, Crucell)
   www.lacdr.nl/
   
   21 – 24 April, 2008
   World vaccine Congress 2008
   Gold sponsor Crucell (zie draadje)
   Congress day two
   11.35 Adenoviral vaccines against emerging and poverty-related diseases
   Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
   Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
   Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
   Dr Jaap Goudsmit, Chief Scientific Officer,
   Crucell
   Ook AdImmune, Vaxin enz
   www.terrapinn.com/2008/wvc_DC/program...
   
5. [verwijderd] 22 november 2007 14:04

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   28-11-2007
   Crucell Company visit
   
   November 30, 2007 in Bangkok, Thailand
   Joint International Tropical
   Medicine Meeting 2007
   Data from the Phase I clinical trial in India, to assess safety and
   efficacy, will be reported.
   
   Mon 03 Dec 2007 - Thu 06 Dec 2007
   Comparability Strategies for Supporting Manufacturing Scale Up of Merck’s HPV Vaccine GARDASIL®/SILGARD®
   Taking a closer look at recent PER.C6 human cell line developments
   Dr Fons UytdeHaag, Director Corporate Scientific
   Affairs, Crucell NV, The Netherlands
   www.iir-events.com/IIR-conf/LifeScien...
   
   December 04 - 06, 2007 · Sheraton San Diego Hotel and Marina · San Diego, CA
   Advancing Clinical and Preclinical Development of Therapeutic Antibodies and Antibody Conjugates
   9:15 Innovation in Human Monoclonal Antibody Production: Transient and Stable High Level Expression in PER.C6 and New Ways to Improve Yields and Lower Investments
   Abstract to come.
   Jaap Goudsmit, M.D., Chief Scientific Officer, Crucell, The Netherlands
   www.ibclifesciences.com/D4173/8074.xml
   
   December 10, 2007 - Merchant Taylor’s Hall, London
   ESN European Mid & Small Caps Seminar
   Crucell
   SNS Securities (The Netherlands).
   www.businesswire.com/portal/site/topi...
   
   Dec. 12
   Concerns about safety have pushed back a trial of a government-developed vaccine that contains adenovirus. The U.S. National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, will hold a meeting of researchers Dec. 12 to determine whether or how to proceed with the vaccine trial.
   www.bloomberg.com/apps/news?pid=20601...
   
   Friday, January 11
   Protein Production Conference
   11:30 Highly Efficient Expression of Recombinant Proteins in PER.C6 Cells: Impact on the Design of Manufacturing Facilities.
   Marco A. Cacciuttolo, Ph.D., Chief Executive Officer, PERCIVIA LLC
   Due to the highly efficient nature of PER.C6® cells both (1) to grow in suspension cultures at extremely high cell densities and (2) to express recombinant product on a per-cell basis without the need for amplification at high specific yields, the PER.C6® Technology Platform has to address the need to manufacture, recover, and purify proteins economically and efficiently. In this presentation, a revolutionary concept for making biologics in small footprint facilities, using disposable technologies is discussed. This design takes advantage of the high specific productivity in each of the Upstream and Downstream unit operations achieved when using the PER.C6® Technology Platform.
   www.chi-peptalk.com/08_PPD_day2.asp
   
   Monday ‐ January 28, 2008
   16.30 – 17.00 ‘Ebola vaccination’
   Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.
   www.ewi.med.uu.nl/CTID/Programme_CTID...
   
   12-02-2008
   Crucell Jaarcijfers 2007 (voorbeurs)
   
   HIV Pathogenesis (X8)
   Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
   Saturday, March 29
   8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
   Dan H. Barouch, Beth Israel Deaconess Medical Center
   Novel Adenovirus Vectors
   Sunday, March 30
   8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
   Jaap Goudsmit, Crucell Holland B.V.
   Flu, TB
   www.keystonesymposia.org/Meetings/Vie...
   
   14-17 April 2008, Oegstgeest, NL
   Development of Biopharmaceuticals as
   Innovative Drugs
   Scientific Advisory Board
   Prof. Dr. E. Hack, Crucell
   Project management and product development (Michel Briejer,Crucell)
   IP issues (Bart Klein, Crucell)
   www.lacdr.nl/
   
   21 – 24 April, 2008
   World vaccine Congress 2008
   Gold sponsor Crucell (zie draadje)
   Congress day two
   11.35 Adenoviral vaccines against emerging and poverty-related diseases
   Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
   Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
   Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
   Dr Jaap Goudsmit, Chief Scientific Officer,
   Crucell
   Ook AdImmune, Vaxin enz
   www.terrapinn.com/2008/wvc_DC/program...
   
   
6. [verwijderd] 23 november 2007 12:32

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   
   28-11-2007
   Crucell Company visit
   
   November 30, 2007 in Bangkok, Thailand
   Joint International Tropical
   Medicine Meeting 2007
   Data from the Phase I clinical trial in India, to assess safety and
   efficacy, will be reported.
   
   Mon 03 Dec 2007 - Thu 06 Dec 2007
   Comparability Strategies for Supporting Manufacturing Scale Up of Merck’s HPV Vaccine GARDASIL®/SILGARD®
   Taking a closer look at recent PER.C6 human cell line developments
   Dr Fons UytdeHaag, Director Corporate Scientific
   Affairs, Crucell NV, The Netherlands
   www.iir-events.com/IIR-conf/LifeScien...
   
   December 04 - 06, 2007 · Sheraton San Diego Hotel and Marina · San Diego, CA
   Advancing Clinical and Preclinical Development of Therapeutic Antibodies and Antibody Conjugates
   9:15 Innovation in Human Monoclonal Antibody Production: Transient and Stable High Level Expression in PER.C6 and New Ways to Improve Yields and Lower Investments
   Abstract to come.
   Jaap Goudsmit, M.D., Chief Scientific Officer, Crucell, The Netherlands
   www.ibclifesciences.com/D4173/8074.xml
   
   Dec. 7, Friday 11:00p.m.
   New Approaches to Develop Potent Human Monoclonal Antibodies Broadly Reactive to Variable Antigens: The Avian Influenza Example.
   Dr. Jaap Goudsmit, Crucell, Leiden, The Netherlands
   www.biotech-calendar.com/sdcal/sandie...
   
   December 10, 2007 - Merchant Taylor’s Hall, London
   ESN European Mid & Small Caps Seminar
   Crucell
   SNS Securities (The Netherlands).
   www.businesswire.com/portal/site/topi...
   
   Dec. 12
   Concerns about safety have pushed back a trial of a government-developed vaccine that contains adenovirus. The U.S. National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, will hold a meeting of researchers Dec. 12 to determine whether or how to proceed with the vaccine trial.
   www.bloomberg.com/apps/news?pid=20601...
   
   Friday, January 11
   Protein Production Conference
   11:30 Highly Efficient Expression of Recombinant Proteins in PER.C6 Cells: Impact on the Design of Manufacturing Facilities.
   Marco A. Cacciuttolo, Ph.D., Chief Executive Officer, PERCIVIA LLC
   Due to the highly efficient nature of PER.C6® cells both (1) to grow in suspension cultures at extremely high cell densities and (2) to express recombinant product on a per-cell basis without the need for amplification at high specific yields, the PER.C6® Technology Platform has to address the need to manufacture, recover, and purify proteins economically and efficiently. In this presentation, a revolutionary concept for making biologics in small footprint facilities, using disposable technologies is discussed. This design takes advantage of the high specific productivity in each of the Upstream and Downstream unit operations achieved when using the PER.C6® Technology Platform.
   www.chi-peptalk.com/08_PPD_day2.asp
   
   Monday ‐ January 28, 2008
   16.30 – 17.00 ‘Ebola vaccination’
   Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.
   www.ewi.med.uu.nl/CTID/Programme_CTID...
   
   12-02-2008
   Crucell Jaarcijfers 2007 (voorbeurs)
   
   HIV Pathogenesis (X8)
   Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
   Saturday, March 29
   8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
   Dan H. Barouch, Beth Israel Deaconess Medical Center
   Novel Adenovirus Vectors
   Sunday, March 30
   8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
   Jaap Goudsmit, Crucell Holland B.V.
   Flu, TB
   www.keystonesymposia.org/Meetings/Vie...
   
   14-17 April 2008, Oegstgeest, NL
   Development of Biopharmaceuticals as
   Innovative Drugs
   Scientific Advisory Board
   Prof. Dr. E. Hack, Crucell
   Project management and product development (Michel Briejer,Crucell)
   IP issues (Bart Klein, Crucell)
   www.lacdr.nl/
   
   21 – 24 April, 2008
   World vaccine Congress 2008
   Gold sponsor Crucell (zie draadje)
   Congress day two
   11.35 Adenoviral vaccines against emerging and poverty-related diseases
   Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
   Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
   Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
   Dr Jaap Goudsmit, Chief Scientific Officer,
   Crucell
   Ook AdImmune, Vaxin enz
   www.terrapinn.com/2008/wvc_DC/program...
   
7. [verwijderd] 25 november 2007 19:07

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   28-11-2007
   Crucell Company visit
   
   November 30, 2007 in Bangkok, Thailand
   Joint International Tropical
   Medicine Meeting 2007
   Data from the Phase I clinical trial in India, to assess safety and
   efficacy, will be reported.
   
   Mon 03 Dec 2007 - Thu 06 Dec 2007
   Comparability Strategies for Supporting Manufacturing Scale Up of Merck’s HPV Vaccine GARDASIL®/SILGARD®
   Taking a closer look at recent PER.C6 human cell line developments
   Dr Fons UytdeHaag, Director Corporate Scientific
   Affairs, Crucell NV, The Netherlands
   www.iir-events.com/IIR-conf/LifeScien...
   
   December 04 - 06, 2007 · Sheraton San Diego Hotel and Marina · San Diego, CA
   Advancing Clinical and Preclinical Development of Therapeutic Antibodies and Antibody Conjugates
   9:15 Innovation in Human Monoclonal Antibody Production: Transient and Stable High Level Expression in PER.C6 and New Ways to Improve Yields and Lower Investments
   Abstract to come.
   Jaap Goudsmit, M.D., Chief Scientific Officer, Crucell, The Netherlands
   www.ibclifesciences.com/D4173/8074.xml
   
   Dec. 7, Friday 11:00p.m.
   New Approaches to Develop Potent Human Monoclonal Antibodies Broadly Reactive to Variable Antigens: The Avian Influenza Example.
   Dr. Jaap Goudsmit, Crucell, Leiden, The Netherlands
   www.biotech-calendar.com/sdcal/sandie...
   
   December 10, 2007 - Merchant Taylor’s Hall, London
   ESN European Mid & Small Caps Seminar
   Crucell
   SNS Securities (The Netherlands).
   www.businesswire.com/portal/site/topi...
   
   Dec. 12
   Concerns about safety have pushed back a trial of a government-developed vaccine that contains adenovirus. The U.S. National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, will hold a meeting of researchers Dec. 12 to determine whether or how to proceed with the vaccine trial.
   www.bloomberg.com/apps/news?pid=20601...
   
   Friday, January 11
   Protein Production Conference
   11:30 Highly Efficient Expression of Recombinant Proteins in PER.C6 Cells: Impact on the Design of Manufacturing Facilities.
   Marco A. Cacciuttolo, Ph.D., Chief Executive Officer, PERCIVIA LLC
   Due to the highly efficient nature of PER.C6® cells both (1) to grow in suspension cultures at extremely high cell densities and (2) to express recombinant product on a per-cell basis without the need for amplification at high specific yields, the PER.C6® Technology Platform has to address the need to manufacture, recover, and purify proteins economically and efficiently. In this presentation, a revolutionary concept for making biologics in small footprint facilities, using disposable technologies is discussed. This design takes advantage of the high specific productivity in each of the Upstream and Downstream unit operations achieved when using the PER.C6® Technology Platform.
   www.chi-peptalk.com/08_PPD_day2.asp
   
   January 23-25, 2008
   Bangkok International Conference on Avian Influenza
   Prof. Albert D.M.E. Osterhaus, Erasmus Medical Centre, Netherlands
   Co-organizers and sponsors : Crucell
   www.biotec.or.th/AIconf2008/home/Conf...
   
   Monday ‐ January 28, 2008
   16.30 – 17.00 ‘Ebola vaccination’
   Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.
   www.ewi.med.uu.nl/CTID/Programme_CTID...
   
   12-02-2008
   Crucell Jaarcijfers 2007 (voorbeurs)
   
   HIV Pathogenesis (X8)
   Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
   Saturday, March 29
   8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
   Dan H. Barouch, Beth Israel Deaconess Medical Center
   Novel Adenovirus Vectors
   Sunday, March 30
   8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
   Jaap Goudsmit, Crucell Holland B.V.
   Flu, TB
   www.keystonesymposia.org/Meetings/Vie...
   
   14-17 April 2008, Oegstgeest, NL
   Development of Biopharmaceuticals as
   Innovative Drugs
   Scientific Advisory Board
   Prof. Dr. E. Hack, Crucell
   Project management and product development (Michel Briejer,Crucell)
   IP issues (Bart Klein, Crucell)
   www.lacdr.nl/
   
   21 – 24 April, 2008
   World vaccine Congress 2008
   Gold sponsor Crucell (zie draadje)
   Congress day two
   11.35 Adenoviral vaccines against emerging and poverty-related diseases
   Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
   Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
   Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
   Dr Jaap Goudsmit, Chief Scientific Officer,
   Crucell
   Ook AdImmune, Vaxin enz
   www.terrapinn.com/2008/wvc_DC/program...
   
8. josti5 28 november 2007 14:09

   auteur info

   • josti5

     Lid sinds: 23 feb 2005

     Laatste bezoek: 28 mrt 2025

   • Aanbevelingen

     Ontvangen: 17886

     Gegeven: 21100

   •    Aantal posts: 34.559

   En?
   
   Was/is het een beetje gezellig tijdens het bedrijfsbezoek???
   
   Hangende koppies?
   Gefrustreerde, vuurrood aangelopen MT-ers?
   Vrolijk rondlopende medewerkers?
   Ontspannen sfeer?
   Onderdrukt enthousiasme onder de presentatoren, of stiekum hopen dat deze dag snel voorbij is?
   
   
9. aossa 28 november 2007 14:46

   auteur info

   • aossa

     Lid sinds: 23 mei 2003

     Laatste bezoek: 27 mrt 2025

   • Aanbevelingen

     Ontvangen: 4053

     Gegeven: 3339

   •    Aantal posts: 17.622

   www.crucell.com/page/downloads/Jaap_G...
   
   Jaap over HIV Adenovirus vector failure etc.
   Wednesday 28th november 10:30 CET
   
10. [verwijderd] 28 november 2007 15:03

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    aossa schreef:

    www.crucell.com/page/downloads/Jaap_G...
    
    Jaap over HIV Adenovirus vector failure etc.
    Wednesday 28th november 10:30 CET
    
    

    Mooi gevonden aossa
    
    Note voor Sammie:
    
    Ad5 probleem geldt dus niet voor Ebola.
    (pagina 31/32)
    
    Dirk
11. [verwijderd] 2 december 2007 12:34

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    
    Mon 03 Dec 2007 - Thu 06 Dec 2007
    Comparability Strategies for Supporting Manufacturing Scale Up of Merck’s HPV Vaccine GARDASIL®/SILGARD®
    Taking a closer look at recent PER.C6 human cell line developments
    Dr Fons UytdeHaag, Director Corporate Scientific
    Affairs, Crucell NV, The Netherlands
    www.iir-events.com/IIR-conf/LifeScien...
    
    December 04 - 06, 2007 · Sheraton San Diego Hotel and Marina · San Diego, CA
    Advancing Clinical and Preclinical Development of Therapeutic Antibodies and Antibody Conjugates
    9:15 Innovation in Human Monoclonal Antibody Production: Transient and Stable High Level Expression in PER.C6 and New Ways to Improve Yields and Lower Investments
    Abstract to come.
    Jaap Goudsmit, M.D., Chief Scientific Officer, Crucell, The Netherlands
    www.ibclifesciences.com/D4173/8074.xml
    
    Dec. 7, Friday 11:00p.m.
    New Approaches to Develop Potent Human Monoclonal Antibodies Broadly Reactive to Variable Antigens: The Avian Influenza Example.
    Dr. Jaap Goudsmit, Crucell, Leiden, The Netherlands
    www.biotech-calendar.com/sdcal/sandie...
    
    December 10, 2007 - Merchant Taylor’s Hall, London
    ESN European Mid & Small Caps Seminar
    Crucell
    SNS Securities (The Netherlands).
    www.businesswire.com/portal/site/topi...
    
    Dec. 12
    Concerns about safety have pushed back a trial of a government-developed vaccine that contains adenovirus. The U.S. National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, will hold a meeting of researchers Dec. 12 to determine whether or how to proceed with the vaccine trial.
    www.bloomberg.com/apps/news?pid=20601...
    
    Friday, January 11
    Protein Production Conference
    11:30 Highly Efficient Expression of Recombinant Proteins in PER.C6 Cells: Impact on the Design of Manufacturing Facilities.
    Marco A. Cacciuttolo, Ph.D., Chief Executive Officer, PERCIVIA LLC
    Due to the highly efficient nature of PER.C6® cells both (1) to grow in suspension cultures at extremely high cell densities and (2) to express recombinant product on a per-cell basis without the need for amplification at high specific yields, the PER.C6® Technology Platform has to address the need to manufacture, recover, and purify proteins economically and efficiently. In this presentation, a revolutionary concept for making biologics in small footprint facilities, using disposable technologies is discussed. This design takes advantage of the high specific productivity in each of the Upstream and Downstream unit operations achieved when using the PER.C6® Technology Platform.
    www.chi-peptalk.com/08_PPD_day2.asp
    
    Monday ‐ January 28, 2008
    16.30 – 17.00 ‘Ebola vaccination’
    Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.
    www.ewi.med.uu.nl/CTID/Programme_CTID...
    
    12-02-2008
    Crucell Jaarcijfers 2007 (voorbeurs)
    
    HIV Pathogenesis (X8)
    Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
    Saturday, March 29
    8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
    Dan H. Barouch, Beth Israel Deaconess Medical Center
    Novel Adenovirus Vectors
    Sunday, March 30
    8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
    Jaap Goudsmit, Crucell Holland B.V.
    Flu, TB
    www.keystonesymposia.org/Meetings/Vie...
    
    14-17 April 2008, Oegstgeest, NL
    Development of Biopharmaceuticals as
    Innovative Drugs
    Scientific Advisory Board
    Prof. Dr. E. Hack, Crucell
    Project management and product development (Michel Briejer,Crucell)
    IP issues (Bart Klein, Crucell)
    www.lacdr.nl/
    
    21 – 24 April, 2008
    World vaccine Congress 2008
    Gold sponsor Crucell (zie draadje)
    Congress day two
    11.35 Adenoviral vaccines against emerging and poverty-related diseases
    Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
    Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
    Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
    Dr Jaap Goudsmit, Chief Scientific Officer,
    Crucell
    Ook AdImmune, Vaxin enz
    www.terrapinn.com/2008/wvc_DC/program...
    
12. [verwijderd] 3 december 2007 17:45

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Weer 1 erbij deze week 5 dec:
    
    Mon 03 Dec 2007 - Thu 06 Dec 2007
    Comparability Strategies for Supporting Manufacturing Scale Up of Merck’s HPV Vaccine GARDASIL®/SILGARD®
    Taking a closer look at recent PER.C6 human cell line developments
    Dr Fons UytdeHaag, Director Corporate Scientific
    Affairs, Crucell NV, The Netherlands
    www.iir-events.com/IIR-conf/LifeScien...
    
    Tue 04 Dec 2007 - Wed 05 Dec 2007 Sofitel Cologne am Roemerturm, Cologne, Germany
    Informa Life Sciences
    Day One: 4th December 2007
    11.30 Progress with vaccines for HIV using adenoviral vectors
    Dr John Shiver, Vice President, Worldwide Basic Research, Franchise Head, Merck Research Labs, USA
    Day Two: 5th December 2007
    09.05 New technologies revolutionizing the influenza vaccine field
    Dr Jan ter Meulen, Executive Director Infectious Diseases, Crucell NV, Netherlands
    www.iir-events.com/IIR-conf/LifeScien...
    
    December 04 - 06, 2007 · Sheraton San Diego Hotel and Marina · San Diego, CA
    Advancing Clinical and Preclinical Development of Therapeutic Antibodies and Antibody Conjugates
    9:15 Innovation in Human Monoclonal Antibody Production: Transient and Stable High Level Expression in PER.C6 and New Ways to Improve Yields and Lower Investments
    Abstract to come.
    Jaap Goudsmit, M.D., Chief Scientific Officer, Crucell, The Netherlands
    www.ibclifesciences.com/D4173/8074.xml
    
    Dec. 7, Friday 11:00p.m.
    New Approaches to Develop Potent Human Monoclonal Antibodies Broadly Reactive to Variable Antigens: The Avian Influenza Example.
    Dr. Jaap Goudsmit, Crucell, Leiden, The Netherlands
    www.biotech-calendar.com/sdcal/sandie...
    
    December 10, 2007 - Merchant Taylor’s Hall, London
    ESN European Mid & Small Caps Seminar
    Crucell
    SNS Securities (The Netherlands).
    www.businesswire.com/portal/site/topi...
    
    Dec. 12
    Concerns about safety have pushed back a trial of a government-developed vaccine that contains adenovirus. The U.S. National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, will hold a meeting of researchers Dec. 12 to determine whether or how to proceed with the vaccine trial.
    www.bloomberg.com/apps/news?pid=20601...
    
    Friday, January 11
    Protein Production Conference
    11:30 Highly Efficient Expression of Recombinant Proteins in PER.C6 Cells: Impact on the Design of Manufacturing Facilities.
    Marco A. Cacciuttolo, Ph.D., Chief Executive Officer, PERCIVIA LLC
    Due to the highly efficient nature of PER.C6® cells both (1) to grow in suspension cultures at extremely high cell densities and (2) to express recombinant product on a per-cell basis without the need for amplification at high specific yields, the PER.C6® Technology Platform has to address the need to manufacture, recover, and purify proteins economically and efficiently. In this presentation, a revolutionary concept for making biologics in small footprint facilities, using disposable technologies is discussed. This design takes advantage of the high specific productivity in each of the Upstream and Downstream unit operations achieved when using the PER.C6® Technology Platform.
    www.chi-peptalk.com/08_PPD_day2.asp
    
    Monday ‐ January 28, 2008
    16.30 – 17.00 ‘Ebola vaccination’
    Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.
    www.ewi.med.uu.nl/CTID/Programme_CTID...
    
    12-02-2008
    Crucell Jaarcijfers 2007 (voorbeurs)
    
    HIV Pathogenesis (X8)
    Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
    Saturday, March 29
    8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
    Dan H. Barouch, Beth Israel Deaconess Medical Center
    Novel Adenovirus Vectors
    Sunday, March 30
    8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
    Jaap Goudsmit, Crucell Holland B.V.
    Flu, TB
    www.keystonesymposia.org/Meetings/Vie...
    
    14-17 April 2008, Oegstgeest, NL
    Development of Biopharmaceuticals as
    Innovative Drugs
    Scientific Advisory Board
    Prof. Dr. E. Hack, Crucell
    Project management and product development (Michel Briejer,Crucell)
    IP issues (Bart Klein, Crucell)
    www.lacdr.nl/
    
    21 – 24 April, 2008
    World vaccine Congress 2008
    Gold sponsor Crucell (zie draadje)
    Congress day two
    11.35 Adenoviral vaccines against emerging and poverty-related diseases
    Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
    Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
    Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
    Dr Jaap Goudsmit, Chief Scientific Officer,
    Crucell
    Ook AdImmune, Vaxin enz
    www.terrapinn.com/2008/wvc_DC/program...
    
    
13. [verwijderd] 8 december 2007 15:26

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    December 10, 2007 - Merchant Taylor’s Hall, London
    ESN European Mid & Small Caps Seminar
    Crucell
    SNS Securities (The Netherlands).
    www.businesswire.com/portal/site/topi...
    
    Dec. 12
    Concerns about safety have pushed back a trial of a government-developed vaccine that contains adenovirus. The U.S. National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, will hold a meeting of researchers Dec. 12 to determine whether or how to proceed with the vaccine trial.
    www.bloomberg.com/apps/news?pid=20601...
    
    2008:
    
    Friday, January 11
    Protein Production Conference
    11:30 Highly Efficient Expression of Recombinant Proteins in PER.C6 Cells: Impact on the Design of Manufacturing Facilities.
    Marco A. Cacciuttolo, Ph.D., Chief Executive Officer, PERCIVIA LLC
    Due to the highly efficient nature of PER.C6® cells both (1) to grow in suspension cultures at extremely high cell densities and (2) to express recombinant product on a per-cell basis without the need for amplification at high specific yields, the PER.C6® Technology Platform has to address the need to manufacture, recover, and purify proteins economically and efficiently. In this presentation, a revolutionary concept for making biologics in small footprint facilities, using disposable technologies is discussed. This design takes advantage of the high specific productivity in each of the Upstream and Downstream unit operations achieved when using the PER.C6® Technology Platform.
    www.chi-peptalk.com/08_PPD_day2.asp
    
    23-25 january 2008
    The Bangkok International Conference on Avian Influenza 2008
    Co-organizers and sponsors :oa Crucell.
    23 January 2008 Development of pandemic influenza vaccines Prof. Albert D.M.E. Osterhaus
    www.biotec.or.th/AIconf2008/home/inde...
    
    Monday ‐ January 28, 2008
    16.30 – 17.00 ‘Ebola vaccination’
    Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.
    www.ewi.med.uu.nl/CTID/Programme_CTID...
    
    12-02-2008
    Crucell Jaarcijfers 2007 (voorbeurs)
    
    HIV Pathogenesis (X8)
    Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
    Saturday, March 29
    8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
    Dan H. Barouch, Beth Israel Deaconess Medical Center
    Novel Adenovirus Vectors
    Sunday, March 30
    8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
    Jaap Goudsmit, Crucell Holland B.V.
    Flu, TB
    www.keystonesymposia.org/Meetings/Vie...
    
    14-17 April 2008, Oegstgeest, NL
    Development of Biopharmaceuticals as
    Innovative Drugs
    Scientific Advisory Board
    Prof. Dr. E. Hack, Crucell
    Project management and product development (Michel Briejer,Crucell)
    IP issues (Bart Klein, Crucell)
    www.lacdr.nl/
    
    21 – 24 April, 2008
    World vaccine Congress 2008
    Gold sponsor Crucell (zie draadje)
    Congress day two
    11.35 Adenoviral vaccines against emerging and poverty-related diseases
    Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
    Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
    Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
    Dr Jaap Goudsmit, Chief Scientific Officer,
    Crucell
    Ook AdImmune, Vaxin enz
    www.terrapinn.com/2008/wvc_DC/program...
    
    
14. [verwijderd] 21 december 2007 15:41

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    2008:
    
    Friday, January 11
    Protein Production Conference
    11:30 Highly Efficient Expression of Recombinant Proteins in PER.C6 Cells: Impact on the Design of Manufacturing Facilities.
    Marco A. Cacciuttolo, Ph.D., Chief Executive Officer, PERCIVIA LLC
    Due to the highly efficient nature of PER.C6® cells both (1) to grow in suspension cultures at extremely high cell densities and (2) to express recombinant product on a per-cell basis without the need for amplification at high specific yields, the PER.C6® Technology Platform has to address the need to manufacture, recover, and purify proteins economically and efficiently. In this presentation, a revolutionary concept for making biologics in small footprint facilities, using disposable technologies is discussed. This design takes advantage of the high specific productivity in each of the Upstream and Downstream unit operations achieved when using the PER.C6® Technology Platform.
    www.chi-peptalk.com/08_PPD_day2.asp
    
    23-25 january 2008
    The Bangkok International Conference on Avian Influenza 2008
    Co-organizers and sponsors :oa Crucell.
    25 January 2008
    Human monoclonal antibodies broadly active against different influenza H5 viruses: ability to cure disease and provide immediate protection against infection
    Jaap Goudsmit, Crucell, The Netherlands
    www.biotec.or.th/AIconf2008/home/inde...
    
    Monday ‐ January 28, 2008
    16.30 – 17.00 ‘Ebola vaccination’
    Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.
    www.ewi.med.uu.nl/CTID/Programme_CTID...
    
    12-02-2008
    Crucell Jaarcijfers 2007 (voorbeurs)
    
    HIV Pathogenesis (X8)
    Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
    Saturday, March 29
    8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
    Dan H. Barouch, Beth Israel Deaconess Medical Center
    Novel Adenovirus Vectors
    Sunday, March 30
    8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
    Jaap Goudsmit, Crucell Holland B.V.
    Flu, TB
    www.keystonesymposia.org/Meetings/Vie...
    
    14-17 April 2008, Oegstgeest, NL
    Development of Biopharmaceuticals as
    Innovative Drugs
    Scientific Advisory Board
    Prof. Dr. E. Hack, Crucell
    Project management and product development (Michel Briejer,Crucell)
    IP issues (Bart Klein, Crucell)
    www.lacdr.nl/
    
    21 – 24 April, 2008
    World vaccine Congress 2008
    Gold sponsor Crucell (zie draadje)
    Congress day two
    11.35 Adenoviral vaccines against emerging and poverty-related diseases
    Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
    Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
    Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
    Dr Jaap Goudsmit, Chief Scientific Officer,
    Crucell
    Ook AdImmune, Vaxin enz
    www.terrapinn.com/2008/wvc_DC/program...
    
15. [verwijderd] 2 januari 2008 18:18

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    
    Friday, January 11
    Protein Production Conference
    11:30 Highly Efficient Expression of Recombinant Proteins in PER.C6 Cells: Impact on the Design of Manufacturing Facilities.
    Marco A. Cacciuttolo, Ph.D., Chief Executive Officer, PERCIVIA LLC
    Due to the highly efficient nature of PER.C6® cells both (1) to grow in suspension cultures at extremely high cell densities and (2) to express recombinant product on a per-cell basis without the need for amplification at high specific yields, the PER.C6® Technology Platform has to address the need to manufacture, recover, and purify proteins economically and efficiently. In this presentation, a revolutionary concept for making biologics in small footprint facilities, using disposable technologies is discussed. This design takes advantage of the high specific productivity in each of the Upstream and Downstream unit operations achieved when using the PER.C6® Technology Platform.
    www.chi-peptalk.com/08_PPD_day2.asp
    
    January 16, 2008
    MorphoSys will hold a public conference call and live audio webcast on January 16, 2008 to provide detailed information on its lead compound MOR103. Additional information will be provided on the Company's website: www.morphosys.com/conferencecalls
    
    23-25 january 2008
    The Bangkok International Conference on Avian Influenza 2008
    Co-organizers and sponsors :oa Crucell.
    25 January 2008
    Human monoclonal antibodies broadly active against different influenza H5 viruses: ability to cure disease and provide immediate protection against infection
    Jaap Goudsmit, Crucell, The Netherlands
    www.biotec.or.th/AIconf2008/home/inde...
    
    Monday ‐ January 28, 2008
    16.30 – 17.00 ‘Ebola vaccination’
    Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.
    www.ewi.med.uu.nl/CTID/Programme_CTID...
    
    12-02-2008
    Crucell Jaarcijfers 2007 (voorbeurs)
    
    HIV Pathogenesis (X8)
    Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
    Saturday, March 29
    8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
    Dan H. Barouch, Beth Israel Deaconess Medical Center
    Novel Adenovirus Vectors
    Sunday, March 30
    8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
    Jaap Goudsmit, Crucell Holland B.V.
    Flu, TB
    www.keystonesymposia.org/Meetings/Vie...
    
    14-17 April 2008, Oegstgeest, NL
    Development of Biopharmaceuticals as
    Innovative Drugs
    Scientific Advisory Board
    Prof. Dr. E. Hack, Crucell
    Project management and product development (Michel Briejer,Crucell)
    IP issues (Bart Klein, Crucell)
    www.lacdr.nl/
    
    21 – 24 April, 2008
    World vaccine Congress 2008
    Gold sponsor Crucell (zie draadje)
    Congress day two
    11.35 Adenoviral vaccines against emerging and poverty-related diseases
    Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
    Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
    Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
    Dr Jaap Goudsmit, Chief Scientific Officer,
    Crucell
    Ook AdImmune, Vaxin enz
    www.terrapinn.com/2008/wvc_DC/program...
    
16. [verwijderd] 4 januari 2008 19:59

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Friday, January 11
    Protein Production Conference
    11:30 Highly Efficient Expression of Recombinant Proteins in PER.C6 Cells: Impact on the Design of Manufacturing Facilities.
    Marco A. Cacciuttolo, Ph.D., Chief Executive Officer, PERCIVIA LLC
    Due to the highly efficient nature of PER.C6® cells both (1) to grow in suspension cultures at extremely high cell densities and (2) to express recombinant product on a per-cell basis without the need for amplification at high specific yields, the PER.C6® Technology Platform has to address the need to manufacture, recover, and purify proteins economically and efficiently. In this presentation, a revolutionary concept for making biologics in small footprint facilities, using disposable technologies is discussed. This design takes advantage of the high specific productivity in each of the Upstream and Downstream unit operations achieved when using the PER.C6® Technology Platform.
    www.chi-peptalk.com/08_PPD_day2.asp
    
    January 16, 2008
    MorphoSys will hold a public conference call and live audio webcast on January 16, 2008 to provide detailed information on its lead compound MOR103. Additional information will be provided on the Company's website: www.morphosys.com/conferencecalls
    
    23-25 january 2008
    The Bangkok International Conference on Avian Influenza 2008
    Co-organizers and sponsors :oa Crucell.
    25 January 2008
    Human monoclonal antibodies broadly active against different influenza H5 viruses: ability to cure disease and provide immediate protection against infection
    Jaap Goudsmit, Crucell, The Netherlands
    www.biotec.or.th/AIconf2008/home/inde...
    
    Monday ‐ January 28, 2008
    16.30 – 17.00 ‘Ebola vaccination’
    Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.
    www.ewi.med.uu.nl/CTID/Programme_CTID...
    
    12-02-2008
    Crucell Jaarcijfers 2007 (voorbeurs)
    
    HIV Pathogenesis (X8)
    Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
    Saturday, March 29
    8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
    Dan H. Barouch, Beth Israel Deaconess Medical Center
    Novel Adenovirus Vectors
    Sunday, March 30
    8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
    Jaap Goudsmit, Crucell Holland B.V.
    Flu, TB
    www.keystonesymposia.org/Meetings/Vie...
    
    14-17 April 2008, Oegstgeest, NL
    Development of Biopharmaceuticals as
    Innovative Drugs
    Scientific Advisory Board
    Prof. Dr. E. Hack, Crucell
    Project management and product development (Michel Briejer,Crucell)
    IP issues (Bart Klein, Crucell)
    www.lacdr.nl/
    
    21 – 24 April, 2008
    World vaccine Congress 2008
    Gold sponsor Crucell (zie draadje)
    Congress day two
    11.35 Adenoviral vaccines against emerging and poverty-related diseases
    Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
    Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
    Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
    Dr Jaap Goudsmit, Chief Scientific Officer,
    Crucell
    Ook AdImmune, Vaxin enz
    www.terrapinn.com/2008/wvc_DC/program...
    
    April 23, 2008 From Concept to Market
    Outsourcing Antibody Development and Production
    08:30-08:50 Keynote Speech:
    Title: TBD
    Dr. Fons UytdeHaag, Senior Director, Crucell Company, Netherlands
    www.bitlifesciences.com/Pepcon2008/Pr...
    
17. gogogoo 11 januari 2008 15:42

    auteur info

    • gogogoo

      Lid sinds: 28 feb 2006

      Laatste bezoek: 10 aug 2023

    • Aanbevelingen

      Ontvangen: 1600

      Gegeven: 808

    •    Aantal posts: 6.042

    crucell.yourbb.nl/viewtopic.php?t=11&...
    
    TheWatersideConference
    February 4-6, 2008
    Miami, Florida.
    
    Scale-Up and Production ofRecombinant and Monoclonal Antibodies
    
    A substantial body of knowledge has been developed on large-scale manufacturing practices for these proteins, but it remains difficult to establish or maintain a fully integrated process than can be reproduced and validated. At the same time, many applications are moving toward the use of human molecules, which present additional development and scale-up challenges.
    Please join us as we explore the problems faced while taking antibody-based products through development and into large-scale production. This meeting will showcase the industry’s more successful efforts as we focus on recent advances in cell culture, analytical, and purification methods; plus trends in facility design and regulatory practices. Posters, workshops, and approximately 60 exhibits will then be used to supplement the program with details on the vital technologies and services needed for success.
    
    TUESDAY, FEBRUARY 5, 2008
    
    11:15-Noon Advances in the Development of a High Cell Density Fed-Batch Process for a Human Cell Line John Chon, Ph.D. – Percivia
    
    www.wilbio.com/pdfs/WMC08_AnnProReg.pdf
18. [verwijderd] 11 januari 2008 16:15

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Gogogoo ik zet hem erbij:
    
    Friday, January 11
    Protein Production Conference
    11:30 Highly Efficient Expression of Recombinant Proteins in PER.C6 Cells: Impact on the Design of Manufacturing Facilities.
    Marco A. Cacciuttolo, Ph.D., Chief Executive Officer, PERCIVIA LLC
    Due to the highly efficient nature of PER.C6® cells both (1) to grow in suspension cultures at extremely high cell densities and (2) to express recombinant product on a per-cell basis without the need for amplification at high specific yields, the PER.C6® Technology Platform has to address the need to manufacture, recover, and purify proteins economically and efficiently. In this presentation, a revolutionary concept for making biologics in small footprint facilities, using disposable technologies is discussed. This design takes advantage of the high specific productivity in each of the Upstream and Downstream unit operations achieved when using the PER.C6® Technology Platform.
    www.chi-peptalk.com/08_PPD_day2.asp
    
    January 16, 2008
    MorphoSys will hold a public conference call and live audio webcast on January 16, 2008 to provide detailed information on its lead compound MOR103. Additional information will be provided on the Company's website: www.morphosys.com/conferencecalls
    
    23-25 january 2008
    The Bangkok International Conference on Avian Influenza 2008
    Co-organizers and sponsors :oa Crucell.
    25 January 2008
    Human monoclonal antibodies broadly active against different influenza H5 viruses: ability to cure disease and provide immediate protection against infection
    Jaap Goudsmit, Crucell, The Netherlands
    www.biotec.or.th/AIconf2008/home/inde...
    
    Monday ‐ January 28, 2008
    16.30 – 17.00 ‘Ebola vaccination’
    Prof. Dr. J. Goudsmit. Crucell Holland BV, NL.
    www.ewi.med.uu.nl/CTID/Programme_CTID...
    
    February 4-6, 2008
    TheWatersideConference
    Miami, Florida.
    Scale-Up and Production ofRecombinant and Monoclonal Antibodies
    A substantial body of knowledge has been developed on large-scale manufacturing practices for these proteins, but it remains difficult to establish or maintain a fully integrated process than can be reproduced and validated. At the same time, many applications are moving toward the use of human molecules, which present additional development and scale-up challenges.
    Please join us as we explore the problems faced while taking antibody-based products through development and into large-scale production. This meeting will showcase the industry’s more successful efforts as we focus on recent advances in cell culture, analytical, and purification methods; plus trends in facility design and regulatory practices. Posters, workshops, and approximately 60 exhibits will then be used to supplement the program with details on the vital technologies and services needed for success.
    TUESDAY, FEBRUARY 5, 2008
    11:15-Noon Advances in the Development of a High Cell Density Fed-Batch Process for a Human Cell Line John Chon, Ph.D. – Percivia
    www.wilbio.com/pdfs/WMC08_AnnProReg.pdf
    
    12-02-2008
    Crucell Jaarcijfers 2007 (voorbeurs)
    
    HIV Pathogenesis (X8)
    Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation
    Saturday, March 29
    8:00 - 11:00 AM Optimization of Vectors and T Lymphocyte Responses
    Dan H. Barouch, Beth Israel Deaconess Medical Center
    Novel Adenovirus Vectors
    Sunday, March 30
    8:00 - 11:00 AM Protection Against Transmission of Mucosal Viruses: What Can Be Learned?
    Jaap Goudsmit, Crucell Holland B.V.
    Flu, TB
    www.keystonesymposia.org/Meetings/Vie...
    
    14-17 April 2008, Oegstgeest, NL
    Development of Biopharmaceuticals as
    Innovative Drugs
    Scientific Advisory Board
    Prof. Dr. E. Hack, Crucell
    Project management and product development (Michel Briejer,Crucell)
    IP issues (Bart Klein, Crucell)
    www.lacdr.nl/
    
    21 – 24 April, 2008
    World vaccine Congress 2008
    Gold sponsor Crucell (zie draadje)
    Congress day two
    11.35 Adenoviral vaccines against emerging and poverty-related diseases
    Development of Ebola, Malaria and Tuberculosis vaccines based on identification of protective antigens and immune correlates
    Delivery technology and route based on inclusion of protective antigen and induction of the appropriate protective immunity
    Specifications for EBO, MAL and TB vaccines based on non-human primate and/or human challenge models
    Dr Jaap Goudsmit, Chief Scientific Officer,
    Crucell
    Ook AdImmune, Vaxin enz
    www.terrapinn.com/2008/wvc_DC/program...
    
    April 23, 2008 From Concept to Market
    Outsourcing Antibody Development and Production
    08:30-08:50 Keynote Speech:
    Title: TBD
    Dr. Fons UytdeHaag, Senior Director, Crucell Company, Netherlands
    www.bitlifesciences.com/Pepcon2008/Pr...
    
19. gogogoo 13 januari 2008 12:58

    auteur info

    • gogogoo

      Lid sinds: 28 feb 2006

      Laatste bezoek: 10 aug 2023

    • Aanbevelingen

      Ontvangen: 1600

      Gegeven: 808

    •    Aantal posts: 6.042

    Bangkok International Conference on Avian Influenza 2008 :
    Integration from Knowledge to Control
    January 23-25, 2008 at Napalai Ballroom, The Dusit Thani, Bangkok, Thailand
    
    25 January 2008
    
    10.10-10.25
    Human monoclonal antibodies broadly active against different influenza H5 viruses: ability to cure disease and provide immediate protection against infection
    Jaap Goudsmit, Crucell N.V., The Netherlands
    www.biotec.or.th/AIconf2008/home/Conf...
    
    Via flosz:
    crucell.yourbb.nl/viewtopic.php?t=11&...
20. [verwijderd] 13 januari 2008 13:04

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    gogogoo schreef:

    Bangkok International Conference on Avian Influenza 2008 :
    Integration from Knowledge to Control
    January 23-25, 2008 at Napalai Ballroom, The Dusit Thani, Bangkok, Thailand
    
    25 January 2008
    
    10.10-10.25
    Human monoclonal antibodies broadly active against different influenza H5 viruses: ability to cure disease and provide immediate protection against infection
    Jaap Goudsmit, Crucell N.V., The Netherlands
    www.biotec.or.th/AIconf2008/home/Conf...
    
    Via flosz:
    crucell.yourbb.nl/viewtopic.php?t=11&...
    

    Stond hier al bij.